Emerald Advisers Inc. PA increased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 893,484 shares of the biotechnology company’s stock after purchasing an additional 18,077 shares during the quarter. Sarepta Therapeutics makes up approximately 1.6% of Emerald Advisers Inc. PA’s investment portfolio, making the stock its 6th biggest position. Emerald Advisers Inc. PA owned approximately 1.39% of Sarepta Therapeutics worth $40,528,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in Sarepta Therapeutics by 4,403.1% in the 1st quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after purchasing an additional 5,175,193 shares during the period. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock worth $143,572,000 after buying an additional 162,543 shares in the last quarter. State Street Corp increased its stake in Sarepta Therapeutics by 21.2% in the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock worth $94,641,000 after buying an additional 559,342 shares in the last quarter. HealthCor Management L.P. increased its stake in Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after buying an additional 481,890 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its stake in Sarepta Therapeutics by 33.4% in the 2nd quarter. Eagle Asset Management Inc. now owns 798,412 shares of the biotechnology company’s stock worth $26,914,000 after buying an additional 200,103 shares in the last quarter. 65.46% of the stock is currently owned by institutional investors.

In other news, SVP Shamim Ruff sold 11,500 shares of the firm’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.60% of the stock is currently owned by company insiders.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 62.44%. The business had revenue of $45.95 million for the quarter, compared to analyst estimates of $41.29 million. During the same period last year, the business earned ($0.95) EPS.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/emerald-advisers-inc-pa-has-40-53-million-position-in-sarepta-therapeutics-inc-srpt/1673701.html.

SRPT has been the subject of a number of analyst reports. Janney Montgomery Scott increased their price target on Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research note on Monday, July 24th. Credit Suisse Group increased their price target on Sarepta Therapeutics from $5.65 to $81.00 and gave the stock an “outperform” rating in a research note on Thursday, September 7th. Nomura reiterated a “buy” rating and issued a $84.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $63.59.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.